BPC-157 Research Peptide

BPC-157 (Body Protection Compound 157; Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; CAS 137525-51-0; MW ~1419.5 Da) is a synthetic pentadecapeptide derived from a partial sequence of a protein isolated from human gastric juice, studied since the 1990s. Its most distinctive published property is acid stability: unlike the large majority of peptides, BPC-157 remains detectable and structurally intact after exposure to simulated gastric juice (pH 1–2, with pepsin) — a finding reported repeatedly across the preclinical literature and one reason it is described as a 'stable gastric pentadecapeptide.' Mechanistically, the compound is studied as a pleiotropic modulator of angiogenesis and the nitric-oxide system rather than as an agonist at a single defined receptor. Hsieh et al. (Journal of Molecular Medicine, 2017) reported that BPC-157 up-regulates VEGFR2 expression and promotes its internalization in vascular endothelial cells, activating the VEGFR2-Akt-eNOS signaling pathway — an effect blocked by dynasore (an endocytosis inhibitor), which places receptor internalization, not simple binding, at the center of the proposed mechanism. A separate line of research (Scientific Reports, 2020) reports modulation of vasomotor tone via the Src-Caveolin-1-eNOS pathway, a related but distinct vascular signaling route.

Preclinical pharmacokinetic characterization (He et al., Frontiers in Pharmacology, 2022) in rats and beagle dogs found an elimination half-life under 30 minutes, with linear pharmacokinetics across the range studied. The compound was rapidly metabolized into smaller peptide fragments and free amino acids and cleared primarily via urine and bile. That short systemic half-life is a consistent parameter across the pharmacokinetic literature and a variable researchers account for in study design. Published preclinical study domains for BPC-157 include: ligament healing (Cerovecki et al., Journal of Orthopaedic Research, 2010 — a rat medial collateral ligament transection model), Achilles tendon transection healing and in-vitro tenocyte proliferation (Journal of Applied Physiology, 2011), myotendinous-junction and muscle-to-bone reattachment repair (multiple Sikiric-group publications, Biomedicines, 2021–2024), spinal cord injury recovery models, and gastrointestinal ulcer and fistula healing models — the tissue-repair domain in which the compound was originally characterized in the 1990s.

The published evidence base for BPC-157 is concentrated disproportionately in one research group (Predrag Sikiric and collaborators at the University of Zagreb), with independent replication outside that group comparatively limited; researchers should weigh that concentration when assessing the literature. DMV Research supplies BPC-157 as a lyophilized powder; each batch ships with a third-party Certificate of Analysis confirming identity (by mass spectrometry) and purity (by HPLC) for research use..